In mouse CRC models, oral L-SeMet suppressed tumor growth and enhanced CD8+ T cell effector activity, highlighting its potential as a dietary selenium–based immunotherapy sensitizer (79). This evidence concerns the gene CD8A and colorectal carcinoma.